Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to treat and prevent hypokalemia. It is available in various formulations for oral and intravenous administration. ## Primary Indications * Treatment of hypokalemia (serum potassium < 3.5 mEq/L). * Prevention of hypokalemia in patients at risk, such as those on diuretics or with significant potassium losses. ## Adult Dosing * **Oral:** * **Treatment of hypokalemia:** Typically 20-100 mEq per day, divided into 2-4 doses. Maximum single oral dose generally 40 mEq. Specific dosing depends on severity of hypokalemia and ongoing losses. * **Prevention of hypokalemia:** Typically 20-40 mEq per day, divided into 1-2 doses. * **Intravenous (IV):** * **Treatment of hypokalemia:** Dosing is highly individualized based on serum potassium levels, clinical status, and ECG findings. A common starting point for mild to moderate hypokalemia may be 10-20 mEq administered over 1-2 hours. For more severe or symptomatic hypokalemia, higher doses (e.g., 20-40 mEq) may be given, often in higher concentrations (up to 40 mEq/L in a large vein) and infused more rapidly (over 30-60 minutes), but *always* with continuous ECG monitoring. * **Maximum infusion rate (general):** For peripheral lines, typically limited to 10 mEq/hour (max 20 mEq/hour in critical care with cardiac monitoring). For central lines, rates up to 20 mEq/hour are often used, and up to 40 mEq/hour in emergent situations with continuous ECG monitoring. **NEVER administer as an IV bolus.** * **Maximum concentration:** Peripheral IV: 40 mEq/L. Central IV: 80-100 mEq/L (higher concentrations may be associated with increased pain and phlebitis). * **Total daily dose:** Usually does not exceed 200 mEq in 24 hours, but may be higher in severe, life-threatening hypokalemia under close monitoring. ## Pediatric Dosing * **Oral:** * **Treatment of hypokalemia:** 2-5 mEq/kg/day divided into 2-4 doses. Maximum total daily dose typically 100 mEq. * **Prevention of hypokalemia:** 1-2 mEq/kg/day divided into 1-2 doses. Maximum total daily dose typically 40 mEq. * **Intravenous (IV):** * Dosing is based on serum potassium and clinical condition. Commonly infused at 0.3-1 mEq/kg/hour. * **Maximum infusion rate:** Generally 0.5 mEq/kg/hour (up to 1 mEq/kg/hour in children with severe hypokalemia and continuous ECG monitoring). * **Maximum concentration:** Typically 40 mEq/L. Higher concentrations (up to 80 mEq/L) may be used in central lines in critically ill children with careful monitoring. * **Total daily dose:** Typically 1-3 mEq/kg/day, not to exceed 200 mEq/day. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Potassium is renally excreted; impaired renal function can lead to hyperkalemia. Dose reductions are often necessary, and monitoring of potassium levels is critical. * **Hepatic Impairment:** No specific dose adjustment, but monitor electrolytes closely. ## Contraindications * Hyperkalemia (serum potassium > 5.5 mEq/L). * Conditions predisposing to hyperkalemia, such as severe renal impairment, untreated Addison's disease, severe burns, or crush injuries. * Certain gastrointestinal conditions (e.g., esophageal obstruction, delayed gastric emptying) when using sustained-release oral formulations due to risk of ulceration. ## Adverse Effects * **Common:** Gastrointestinal upset (nausea, vomiting, diarrhea, abdominal pain), especially with oral administration. * **Serious:** Hyperkalemia (especially with rapid IV infusion, excessive doses, or in patients with renal impairment). Symptoms include paresthesias, muscle weakness, paralysis, cardiac arrhythmias (e.g., peaked T waves, flattened P waves, widened QRS, cardiac arrest), hypotension. * **IV specific:** Phlebitis, pain, and burning at the injection site, especially with higher concentrations or rapid infusion. ## Key Drug Interactions * **Potassium-sparing diuretics** (e.g., spironolactone, amiloride, triamterene): Increased risk of hyperkalemia. * **ACE inhibitors, ARBs, NSAIDs, beta-blockers, cyclosporine, tacrolimus:** Can increase serum potassium levels, increasing the risk of hyperkalemia. * **Corticosteroids:** Can cause potassium loss, potentially antagonizing the effect of KCl. * **Digitalis glycosides:** Hypokalemia can potentiate digitalis toxicity. Hyperkalemia can decrease digitalis effectiveness. * **Sodium polystyrene sulfonate:** Used to treat hyperkalemia, should not be administered concurrently with potassium supplements. ## Monitoring * Serum potassium levels (frequently, especially during IV therapy, initiation of oral therapy, or dose changes). * Renal function (BUN, creatinine). * ECG monitoring for signs of hyperkalemia, particularly during rapid IV administration. * Signs and symptoms of hypokalemia and hyperkalemia. * Fluid balance. ## Clinical Pearls * Oral formulations should be taken with meals or after meals to minimize gastrointestinal irritation. * Sustained-release oral formulations may be preferred for long-term use to improve compliance and reduce gastrointestinal side effects, but require adequate gastrointestinal motility. * IV potassium should *always* be diluted and administered slowly with continuous monitoring. Never give IV KCl undiluted or as a rapid bolus. * The goal of potassium replacement is to normalize serum potassium levels without causing hyperkalemia. * Correction of hypokalemia should be done cautiously in patients with digitalis toxicity. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and local institutional protocols for definitive guidance. Clinical decisions should be based on individual patient assessment.*